Cabozantinib, approved by the FDA for renal cell carcinoma and medullary thyroid carcinoma, targets multiple receptor tyrosine kinases, including MET, RET, AXL, TRKA, and TRKB [42,43,44]. This evidence concerns the gene NTRK1 and medullary thyroid gland carcinoma.